Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C27H26F3N3O2.3C4H4O4 |
| Molecular Weight | 1311.2354 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.FC(F)(F)OC1=CC=CC(CN2CCC(CC2)N3[C@@H](C4=CC=CC=C4)C5=CC=CC=C5NC3=O)=C1.FC(F)(F)OC6=CC=CC(CN7CCC(CC7)N8[C@@H](C9=CC=CC=C9)C%10=CC=CC=C%10NC8=O)=C6
InChI
InChIKey=WOIRJIDJKVWHJX-CVZQVWBPSA-N
InChI=1S/2C27H26F3N3O2.3C4H4O4/c2*28-27(29,30)35-22-10-6-7-19(17-22)18-32-15-13-21(14-16-32)33-25(20-8-2-1-3-9-20)23-11-4-5-12-24(23)31-26(33)34;3*5-3(6)1-2-4(7)8/h2*1-12,17,21,25H,13-16,18H2,(H,31,34);3*1-2H,(H,5,6)(H,7,8)/b;;3*2-1+/t2*25-;;;/m00.../s1
Afacifenacin is being developed by Sumitomo Dainippon Pharma (formerly Dainippon Sumitomo Pharma) and Sunovion Pharmaceuticals as an orally administered therapy for overactive bladder and nocturia. Afacifenacin is a new antimuscarinic that possesses the dual
pharmacological actions of non-selective muscarinic receptor
antagonist and inhibition of the bladder afferent pathway
through sodium-channel blockade. Afacifenacin is in Phase II clinical tirals for the treatment of Nocturia by Nippon Shinyaku.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
133082921
Created by
admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
|
PRIMARY | |||
|
500593-73-7
Created by
admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
|
PRIMARY | |||
|
V6IS459I5G
Created by
admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
|
PRIMARY |
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
